Overview

Update
IPO / Stock
Went Public on Mar 3, 2016 / NASDAQ:SNDX
Total Equity Funding
$157.33M in 5 Rounds from 14 Investors
Headquarters:
Waltham, MA
Description:
Syndax Pharmaceuticals is focused on developing an HDAC inhibitor for solid tumors and hematological tumors.
Founders:
Categories:
Pharmaceutical, Biotechnology, Clinical Trials
Website:
http://www.syndax.com
Social:

Funding Rounds (7) - $168.28M

Update
DateAmount / RoundValuationLead InvestorInvestors
Aug, 2015$80M / Series C12
Sep, 2014$4.95M / Debt Financing0
Feb, 2014$1.73M / Venture0
Aug, 2013$26.6M / Series B4
Apr, 2010$6.01M / Debt Financing0
Mar, 2010$9M / Series A5
Apr, 2007$40M / Series A5

Current Team (4)

Update

Board Members and Advisors (3)

Update

Offices/Locations (1)

Update
  • Headquarters

    460 Totten Pond Road

    Suite 650

    Waltham, MA 02451

    USA

Past Team (2)

Update

Images (1)

Update

Add Acquisitions

Add Products

Add Sub Organizations

Add Competitors

Add Memberships

Add Customers

Add Partners

Add Videos